accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies.
Our partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products we develop.
Our pipeline is comprised of innovative therapeutic product candidates that we believe have the potential for value creation using our partnership-enabled business model.
We are led by a highly accomplished, multidisciplinary management team and board of directors with extensive experience in all phases of therapeutic device development.
Our two late-stage flagship technologies are designed to address large unmet needs associated with the treatment of hypertension, a significant risk factor for death worldwide and atherosclerotic artery disease, the leading cause of mortality worldwide.
BackBeat CNT™ is a patented bioelectronic treatment for hypertension that is designed to drive an immediate, substantial and persistent reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction.
Virtue SAB is a patented drug/device combination product candidate for the treatment of artery disease designed to deliver a proprietary extended release formulation of sirolimus, SirolimusEFR, during balloon angioplasty without the need for balloon coating or a permanent implant.
Virtue® SAB is not approved for commercial use in the US
BackBeat CNT™ is not approved for commercial use in the US
© 2023 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01